Lexaria Biosciences Corp. was initially created in 2004 and for roughly a decade was focused on the resource industry. It changed its business focus in 2014 and is a publicly traded company in both the USA and Canada. US: LXRP Canada: LXX Lexaria operates four subsidiary companies each operating in different sectors of the economy. Lexaria Nicotine Corp., Lexaria Pharmaceutical Corp., Lexaria Hemp Co., and Lexaria CanPharm Corp. each exist to more independently pursue business opportunities in their respective areas of interest.
The pharmaceutical and nicotine industries are each among the largest in the world. The global tobacco market is US$760 billion, excluding China. If all forms of nicotine are included, and if the Chinese market is included, then the global nicotine market is estimated at roughly US$1,000 billion per year. The nicotine industry is even larger if associated health care costs are considered. The global pharmaceutical industry was estimated at US$1,050 billion in 2017. Other industries that Lexaria serves are together work another ~US$250 billion.
Lexaria’s DehydraTECHTM technology is patent-granted in the USA and Australia for the delivery of nicotine. It is patent-pending in over 40 other countries around the word. Lexaria Nicotine Corp holds the exclusive global license from its parent company Lexaria Bioscience Corp, for commercial opportunities related to nicotine delivery that utilizes DehyraTECH. Lexaria’s intellectual property is quite strong and includes composition of matter patents as well as process patents. As of September 2018 there are over 50 Lexaria patents pending and an expectation that there will be more than 100 patents pending by the end of 2019.
Nicotine is a powerful drug and can be harmful or even fatal at higher doses. There are few if any good reasons for young people to have any exposure to nicotine even under the strictest medical circumstances. There is no medical justification for smoking cigarettes: nicotine administration via smoking should always be avoided. Very small amounts of nicotine received in a non-combustible form are not known to cause significant negative health effects. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm601039.htm According to Public Health England, an arm of the Government of the UK, “The risks of nicotine use are likely to be very low or negligible. NRT is safe and licenced for use in pregnancy and for people with cardiovascular disease”. https://www.gov.uk/government/news/four-in-10-smokers-incorrectly-think-nicotine-causes-cancer
Lexaria Nicotine Corp does not manufacture or sell any nicotine products. What we do is license our patented technology to other companies that want to deliver nicotine in disruptive new product classes that offer reduced harm compared to traditional cigarettes. Several terms are being used today to describe the possibility of moving society away from combustible cigarettes: Reduced Risk; Reduced Harm; Risk Reduction; Combustion-Free; Smokeless. What all these terms have in common is the desire to recognize the need of supplying nicotine to those who wish to use it, in a manner that is less harmful than combustible cigarettes. Lexaria Nicotine Corp wants to help save lives by offering our technology to reduced-risk nicotine manufacturers and helping current or prospective smokers to choose a reduced harm alternative.
Coronavirus (COVID-19) is a respiratory illness that first emerged from an animal source but now spreads quite easily from person to person. There is currently no vaccine against Coronavirus and it is unlikely that one will be developed before 2021. There is currently no specific antiviral treatment for COVID-19, but many existing and experimental drugs are being tested to learn of their effectiveness. Lexaria is working, both independently and with others, to learn whether DehydraTECH might deliver some of these drugs more efficiently into the human bloodstream to better stop or treat COVID-19.